Abstract
The heart and vascular system represent major targets of the thyroid hormone action, and marked changes occur in cardiac electro-mechanical function of patients with hyper-hypothyroidism. Thyroid hormones exert their effects through both genomic (nuclear) and nongenomic (extranuclear) mechanisms. Understanding the cellular mechanisms of thyroid hormone action on the heart and cardiovascular system is the basis to explain the changes in cardiac output, cardiac contractility, blood pressure, vascular resistance, and rhythm abnormalities secondary to thyroid dysfunction. Not only overt, but also subclinical thyroid diseases have been associated with systolic and diastolic cardiac abnormalities, and with alterations of well known cardiovascular risk factors. Moreover, the early diagnosis and treatment of thyroid diseases restore to normal most of the cardiovascular changes. Nowadays, it is becoming increasingly evident that, like a vicious circle, acute and chronic cardiovascular diseases may influence thyroid hormone metabolism, which, in turn, can contribute to cardiovascular impairment progression.
Keywords: Thyroid hormones, cardiovascular disease, thyroid dysfunction
Current Drug Therapy
Title: Thyroid Hormones and Cardiovascular System: From Bench to Bedside
Volume: 5 Issue: 1
Author(s): Pasquale Di Conza, Flora Affuso and Serafino Fazio
Affiliation:
Keywords: Thyroid hormones, cardiovascular disease, thyroid dysfunction
Abstract: The heart and vascular system represent major targets of the thyroid hormone action, and marked changes occur in cardiac electro-mechanical function of patients with hyper-hypothyroidism. Thyroid hormones exert their effects through both genomic (nuclear) and nongenomic (extranuclear) mechanisms. Understanding the cellular mechanisms of thyroid hormone action on the heart and cardiovascular system is the basis to explain the changes in cardiac output, cardiac contractility, blood pressure, vascular resistance, and rhythm abnormalities secondary to thyroid dysfunction. Not only overt, but also subclinical thyroid diseases have been associated with systolic and diastolic cardiac abnormalities, and with alterations of well known cardiovascular risk factors. Moreover, the early diagnosis and treatment of thyroid diseases restore to normal most of the cardiovascular changes. Nowadays, it is becoming increasingly evident that, like a vicious circle, acute and chronic cardiovascular diseases may influence thyroid hormone metabolism, which, in turn, can contribute to cardiovascular impairment progression.
Export Options
About this article
Cite this article as:
Conza Di Pasquale, Affuso Flora and Fazio Serafino, Thyroid Hormones and Cardiovascular System: From Bench to Bedside, Current Drug Therapy 2010; 5 (1) . https://dx.doi.org/10.2174/1574885511005010036
DOI https://dx.doi.org/10.2174/1574885511005010036 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neutrophil Function in Severe Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Potential Strategies for Minimizing Mechanism-Based Inhibition of Cytochrome P450 3A4
Current Pharmaceutical Design New Antimicrobial Approaches: Reuse of Old Drugs
Current Drug Targets Gene Therapy for Osteoinduction
Current Gene Therapy Cognition and Emotions in Recurrent Depressive Disorders - The Role of Inflammation and the Kynurenine Pathway
Current Pharmaceutical Design Living Heart Valve and Small-Diameter Artery Substitutes - An Emerging Field for Intellectual Property Development
Recent Patents on Biotechnology Anesthetic-induced Myocardial Conditioning: Molecular Fundamentals and Scope
Current Medicinal Chemistry A Glycemic Threshold of 90 mg/dl Promotes Early Signs of Atherosclerosis in Apparetly Healthy Overweight/Obese Subjects
Endocrine, Metabolic & Immune Disorders - Drug Targets Biogenic Peptides and Their Potential Use
Current Pharmaceutical Design Quantitative Analysis in Cardiovascular Imaging: Current Status
Current Medical Imaging Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD
Current Cardiology Reviews Risk Scores and Prediction Models in Chronic Heart Failure: A Comprehensive Review
Current Pharmaceutical Design The Role of Transforming Growth Factor-β in Cardiac Fibrosis
Current Enzyme Inhibition Experimental Antioxidant Biotherapy for Protection of the Vascular Wall by Modified Forms of Superoxide Dismutase and Catalase
Current Pharmaceutical Design Preventing Type 2 Diabetes Mellitus: Room for Residual Risk Reduction After Lifestyle Changes?
Current Pharmaceutical Design Oxaliplapin and Capecitabine (XELOX) Based Chemotherapy in the Treatment of Metastatic Colorectal Cancer: The Right Choice in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs in Cancer Therapy: From Bench to Bedside
Current Cancer Therapy Reviews Understanding and Avoiding Antiretroviral Adverse Events
Current Pharmaceutical Design Advances in Methods for Therapeutic Peptide Discovery, Design and Development
Current Pharmaceutical Biotechnology ACE2 and Diabetic Complications
Current Pharmaceutical Design